Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $418,240.96 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 7,136 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

William Richard White also recently made the following trade(s):

• On Friday, November 1st, William Richard White sold 201 shares of Disc Medicine stock. The shares were sold at an average price of $46.37, for a total value of $9,320.37.
• On Tuesday, October 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $51.31, for a total value of $10,313.31.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $63.33 on Friday. The firm has a market capitalization of $1.88 billion, a P/E ratio of -17.26 and a beta of 0.60. The stock has a 50 day moving average price of $49.66 and a 200-day moving average price of $43.48. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. On average, equities analysts forecast that Disc Medicine, Inc. will post -4.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds have recently bought and sold shares of IRON. Atlas Venture Life Science Advisors LLC increased its stake in shares of Disc Medicine by 9.7% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock valued at $113,101,000 after purchasing an additional 222,223 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after buying an additional 969,834 shares in the last quarter. Deerfield Management Company L.P. Series C raised its stake in Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after buying an additional 357,730 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Disc Medicine by 59.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after acquiring an additional 353,382 shares in the last quarter. Finally, Logos Global Management LP purchased a new stake in shares of Disc Medicine in the second quarter worth $41,690,000. Institutional investors own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on IRON shares. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research note on Monday. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research report on Tuesday. Scotiabank increased their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Wells Fargo & Company started coverage on Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target on the stock. Finally, Jefferies Financial Group initiated coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price objective for the company. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine presently has an average rating of “Buy” and a consensus target price of $80.20.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.